Remedy Plan Therapeutics

Biotechnology ResearchMaryland, United States11-50 Employees

Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedy’s groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. We are advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.

Remedy's lead asset is RPT1G. With a favorable efficacy and tolerability profile, RPT1G will be advancing to the clinic in 2024.

Sign up for free to view info

Email Format Employee directory